Alnylam Pharmaceuticals, Inc. (ALNY)
$
314.94
-7.70 (-2.44%)
Key metrics
Financial statements
Free cash flow per share
-0.5813
Market cap
41.1 Billion
Price to sales ratio
17.4884
Debt to equity
11.2759
Current ratio
3.0385
Income quality
0.1673
Average inventory
72 Million
ROE
-5.0933
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of innovative therapeutics based on ribonucleic acid interference. The company reported selling, general, and administrative expenses of $975,526,000.00 indicating its operational overhead costs. Additionally, the company incurred an interest expense of $141,858,000.00 reflecting its debt servicing obligations. A net loss of -$278,157,000.00 was reported, indicating challenges in its operations. With its stock identified by the symbol 'ALNY' in the market, the weighted average number of diluted shares outstanding is 127,651,000.00 reflecting potential dilution effects. Alnylam's pipeline of investigational RNAi therapeutics addresses a range of conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Marketed products such as ONPATTRO (patisiran), GIVLAARI, and OXLUMO highlight its commitment to addressing unmet medical needs. Furthermore, the company is advancing multiple candidates in its pipeline, including givosiran and cemdisiran, enhancing its portfolio with potential therapies for various diseases. Strategic collaborations with prominent partners like Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme bolster its development capabilities. The stock is priced at $322.64 positioning it in the higher-end market. It has an average trading volume of 933,406.00 indicating moderate liquidity. With a mid-range market capitalization of $41,064,396,720.00 the company is a steady performer in the competitive landscape. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and growth within the field. Alnylam continues to enhance its position through collaborations and partnerships, unlocking new avenues for discovering and delivering RNAi therapeutics. The company's focus on cutting-edge science and strategic alliances marks it as a noteworthy entity in advancing healthcare solutions and addressing complex diseases. As it navigates its challenges, Alnylam remains committed to its vision of transforming the treatment landscape through pioneering biopharmaceutical innovations.
Is Alnylam Pharmaceuticals, Inc. (ALNY) a good investment?
Investing in Alnylam Pharmaceuticals, Inc. (ALNY) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Alnylam Pharmaceuticals, Inc. (ALNY)'s stock forecast?
Analysts predict Alnylam Pharmaceuticals, Inc. stock to fluctuate between $205.87 (low) and $333.70 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alnylam Pharmaceuticals, Inc.'s market capitalization?
As of 2025-07-11, Alnylam Pharmaceuticals, Inc.'s market cap is $41,064,396,720, based on 130,388,000 outstanding shares.
How does Alnylam Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Alnylam Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alnylam Pharmaceuticals, Inc. (ALNY) stock?
To buy Alnylam Pharmaceuticals, Inc. (ALNY) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALNY. Place an order (Market, Limit, etc.).
What is the best time to invest in Alnylam Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alnylam Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $2,248,243,000 | EPS: -$2.16 | Growth: -38.64%.
Where can I find Alnylam Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.alnylam.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alnylam Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Alnylam Pharmaceuticals, Inc. stock?
All-time high: $333.70 (2025-07-03) | All-time low: $117.58 (2022-05-12).
What are the key trends affecting Alnylam Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and onl.
fool.com
Many investors love the "big mo." That's short for "big momentum.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The results demonstrate that vutrisiran, which rapi.
zacks.com
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
seekingalpha.com
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler – Chief Commercial Officer Pushkal Garg – Chief Medical Officer Jeff Poulton – Chief Financial Officer Conference Call Participants Tazeen Ahmad – Bank of America Gena Wang – Barclays Teraesa Vitelli – Scotiabank Ellie Merle – UBS Gary Nachman – Raymond James Ritu Baral – TD Cowen Kostas Biliouris – BMO Capital Markets Luca Issi – RBC Capital Markets Paul Matteis – Stifel Mike Ulz – Morgan Stanley Operator Good morning ladies and gentlemen and welcome to the Alnylam Pharmaceuticals Q1 2025 Earnings Conference Call. At this time, all lines are in a listen-only mode.
zacks.com
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago, Illinois.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.
globenewswire.com
Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering.
See all news
